All Stories

  1. Early Vocal Development in TSC Predicts Language, But Not Autism Outcomes
  2. Developmental Trajectories of Adaptive Functioning and Behavior Problems in Children With Co-Occurring Tuberous Sclerosis Complex and Autism Spectrum Disorder, With and Without Seizures
  3. Neurodevelopmental Outcomes from the PREVeNT Trial
  4. Electroencephalogram (EEG) Spike Metrics Discriminate Impending Epileptic Spasms From Other Seizures in Children With Tuberous Sclerosis Complex: A Pilot Study
  5. Arrayed CRISPR/Cas9 Loss-Of-Function Screen in a Neuronal Model of Adaptor Protein Complex 4 Deficiency Identifies Modulators of ATG9A Trafficking
  6. Construction destruction: Contribution of dyregulated proteostasis to neurodevelopmental disorders
  7. Human TSC2 mutant cells exhibit aberrations in early neurodevelopment accompanied by changes in the DNA Methylome
  8. A Hybrid 2D‐to‐3D in vitro Differentiation Platform Improves Outcomes of Cerebral Cortical Organoid Generation in hiPSCs
  9. Drug Resistant Epilepsy in Tuberous Sclerosis Complex is Associated with TSC2 Genotype: More Findings from the PREVeNT Trial
  10. AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient
  11. Human TSC2 Mutant Cells Exhibit Aberrations in Early Neurodevelopment Accompanied by Changes in the DNA Methylome
  12. Gene replacement therapies for inherited disorders of neurotransmission: Current progress in succinic semialdehyde dehydrogenase deficiency
  13. The role of TSC1 and TSC2 proteins in neuronal axons
  14. A roadmap for SHANK3-related Epilepsy Research: recommendations from the 2023 strategic planning workshop
  15. Rescue of Impaired Blood-Brain Barrier in Tuberous Sclerosis Complex Patient Derived Neurovascular Unit
  16. Non-canonical functions of a mutant TSC2 protein in mitotic division
  17. Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial
  18. Increased degradation of FMRP contributes to neuronal hyperexcitability in tuberous sclerosis complex
  19. Intrathecal AAV9/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies
  20. Large 22q13.3 deletions perturb peripheral transcriptomic and metabolomic profiles in Phelan-McDermid syndrome
  21. Non-Canonical Functions of a Mutant TSC2 Protein in Mitotic Division
  22. GENE TARGET: A framework for evaluating Mendelian neurodevelopmental disorders for gene therapy
  23. Tubers affecting the fusiform face area are associated with autism diagnosis
  24. The clinical and molecular spectrum of ZFYVE26-associated hereditary spastic paraplegia: SPG15
  25. Direct-to-Consumer Recruitment Methods for Clinical Trials for Rare Diseases: A Novel Approach for Testing the Application of Targeted Social Media Messaging to Aid in Accrual Into Research Studies (Preprint)
  26. Direct-to-Consumer Recruitment Methods for Clinical Trials for Rare Diseases: A Novel Approach for Testing the Application of Targeted Social Media Messaging to Aid in Accrual Into Research Studies (Preprint)
  27. Novel CAPN1 missense variants in complex hereditary spastic paraplegia with early‐onset psychosis
  28. AP-4-mediated axonal transport controls endocannabinoid production in neurons
  29. Single-cell dissection of the human brain vasculature
  30. Convergent Cerebrospinal Fluid Proteomes and Metabolic Ontologies in Humans and Animal Models of Rett Syndrome
  31. Endothelial GNAQ p.R183Q Increases ANGPT2 (Angiopoietin-2) and Drives Formation of Enlarged Blood Vessels
  32. Enhanced prime editing systems by manipulating cellular determinants of editing outcomes
  33. Epilepsy Is Heterogeneous in Early-Life Tuberous Sclerosis Complex
  34. Phenotypic characterization of Cdkl5-knockdown neurons establishes elongated cilia as a functional assay for CDKL5 Deficiency Disorder
  35. Loss of Tsc1 in cerebellar Purkinje cells induces transcriptional and translation changes in FMRP target transcripts
  36. Factors influencing the acute pentylenetetrazole‐induced seizure paradigm and a literature review
  37. Balancing serendipity and reproducibility: Pluripotent stem cells as experimental systems for intellectual and developmental disorders
  38. 16p11.2 deletion is associated with hyperactivation of human iPSC-derived dopaminergic neuron networks and is rescued by RHOA inhibition in vitro
  39. Generation and characterization of human induced pluripotent stem cells (iPSCs) from three male and three female patients with CDKL5 Deficiency Disorder (CDD)
  40. Generation and characterization of six human induced pluripotent stem cell lines (iPSC) from three families with AP4M1-associated hereditary spastic paraplegia (SPG50)
  41. Shifted phase of EEG cross-frequency coupling in individuals with Phelan-McDermid syndrome
  42. Single-cell dissection of the human cerebrovasculature in health and disease
  43. Loss of Tsc1 in cerebellar Purkinje cells induces transcriptional and translation changes in FMRP target transcripts
  44. A randomized double-blind controlled trial of everolimus in individuals with PTEN mutations: Study design and statistical considerations
  45. Brief Report: Role of Parent-Reported Executive Functioning and Anxiety in Insistence on Sameness in Individuals with Germline PTEN Mutations
  46. Early Pandemic Experiences of Autistic Adults: Predictors of Psychological Distress
  47. Cross-level analysis of molecular and neurobehavioral function in a prospective series of patients with germline heterozygous PTEN mutations with and without autism
  48. Tuber Locations Associated with Infantile Spasms Map to a Common Brain Network
  49. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
  50. Brief Report: Impact of COVID-19 on Individuals with ASD and Their Caregivers: A Perspective from the SPARK Cohort
  51. Correction: Low-level mosaicism in tuberous sclerosis complex: prevalence, clinical features, and risk of disease transmission
  52. A Cell-Based Assay Optimized for High-Content Cilia Imaging with Primary Rat Hippocampal Neurons
  53. Epilepsy Risk Prediction Model for Patients With Tuberous Sclerosis Complex
  54. Editorial: Biomarkers to Enable Therapeutics Development in Neurodevelopmental Disorders
  55. Tuberous sclerosis: a review of the past, present, and future
  56. The Impact of COVID-19 on Individuals With Intellectual and Developmental Disabilities: Clinical and Scientific Priorities
  57. Author Correction: Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders
  58. Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile
  59. Polymicrogyria is Associated With Pathogenic Variants in PTEN
  60. Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders
  61. Defining the clinical, molecular and imaging spectrum of adaptor protein complex 4-associated hereditary spastic paraplegia
  62. Pilot Study of Neurodevelopmental Impact of Early Epilepsy Surgery in Tuberous Sclerosis Complex
  63. Correction: Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders
  64. Phenotypic Screen with TSC-Deficient Neurons Reveals Heat-Shock Machinery as a Druggable Pathway for mTORC1 and Reduced Cilia
  65. Psychometric Study of the Social Responsiveness Scale in Phelan–McDermid Syndrome
  66. Author Correction: Neuronal activity regulates DROSHA via autophagy in spinal muscular atrophy
  67. Diffusion Tensor Imaging Abnormalities in the Uncinate Fasciculus and Inferior Longitudinal Fasciculus in Phelan-McDermid Syndrome
  68. Epilepsy and Neurodevelopmental Comorbidities in Tuberous Sclerosis Complex: A Natural History Study
  69. Tau: A Novel Entry Point for mTOR-Based Treatments in Autism Spectrum Disorder?
  70. Deep learning in rare disease. Detection of tubers in tuberous sclerosis complex
  71. Auditory Processing of Speech and Tones in Children With Tuberous Sclerosis Complex
  72. Learning to Detect Brain Lesions from Noisy Annotations
  73. Posterior Neocortex-Specific Regulation of Neuronal Migration by CEP85L Identifies Maternal Centriole-Dependent Activation of CDK5
  74. Loss of ap4s1 in zebrafish leads to neurodevelopmental defects resembling spastic paraplegia 52
  75. A novel approach to conducting clinical trials in the community setting: utilizing patient-driven platforms and social media to drive web-based patient recruitment
  76. Psychiatric and Medical Profiles of Autistic Adults in the SPARK Cohort
  77. Recent advances in human stem cell-based modeling of Tuberous Sclerosis Complex
  78. Beliefs in vaccine as causes of autism among SPARK cohort caregivers
  79. Language predictors of autism spectrum disorder in young children with tuberous sclerosis complex
  80. Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking
  81. Lesion-Constrained Electrical Source Imaging
  82. Modeling Neurodevelopmental Deficits in Tuberous Sclerosis Complex with Stem Cell Derived Neural Precursors and Neurons
  83. The Connectivity Fingerprint of the Fusiform Gyrus Captures the Risk of Developing Autism in Infants with Tuberous Sclerosis Complex
  84. EEG Spectral Features in Sleep of Autism Spectrum Disorders in Children with Tuberous Sclerosis Complex
  85. Early white matter development is abnormal in tuberous sclerosis complex patients who develop autism spectrum disorder
  86. Scalp EEG spikes predict impending epilepsy in TSC infants: A longitudinal observational study
  87. Neurobehavioral phenotype of autism spectrum disorder associated with germline heterozygous mutations in PTEN
  88. Biallelic mutations in TSC2 lead to abnormalities associated with cortical tubers in human iPSC-derived neurons
  89. Generation and characterization of six human induced pluripotent stem cell lines (iPSC) from three families with AP4B1-associated hereditary spastic paraplegia (SPG47)
  90. A framework for the investigation of rare genetic disorders in neuropsychiatry
  91. Exome sequencing of 457 autism families recruited online provides evidence for autism risk genes
  92. Early patterns of functional brain development associated with autism spectrum disorder in tuberous sclerosis complex
  93. Reproducibility of Structural and Diffusion Tensor Imaging in the TACERN Multi-Center Study
  94. Resting‐State fMRI Networks in Children with Tuberous Sclerosis Complex
  95. Increased electroencephalography connectivity precedes epileptic spasm onset in infants with tuberous sclerosis complex
  96. The Evolution of Subclinical Seizures in Children With Tuberous Sclerosis Complex
  97. White matter mean diffusivity correlates with myelination in tuberous sclerosis complex
  98. Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders
  99. Chronic mTORC1 inhibition rescues behavioral and biochemical deficits resulting from neuronal Depdc5 loss in mice
  100. Low-level mosaicism in tuberous sclerosis complex: prevalence, clinical features, and risk of disease transmission
  101. Genetic Etiologies, Diagnosis, and Treatment of Tuberous Sclerosis Complex
  102. Impacting development in infants with tuberous sclerosis complex: Multidisciplinary research collaboration.
  103. Tuberous Sclerosis Complex Genotypes and Developmental Phenotype
  104. Probing Mechanical Properties of Brain in a Tuberous Sclerosis Model of Autism
  105. Translational Medicine Strategies in Drug Development for Neurodevelopmental Disorders
  106. Volumetric Analysis of the Basal Ganglia and Cerebellar Structures in Patients with Phelan-McDermid Syndrome
  107. Discovering translational biomarkers in neurodevelopmental disorders
  108. Electrographic spikes are common in wildtype mice
  109. High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex
  110. Motion-robust diffusion compartment imaging using simultaneous multi-slice acquisition
  111. Yield of Emergent Neuroimaging in Patients With Sturge-Weber Syndrome Presenting With Acute Neurologic Symptoms
  112. Data-driven analyses revealed the comorbidity landscape of tuberous sclerosis complex
  113. Longitudinal effects of everolimus on white matter diffusion in Tuberous Sclerosis Complex
  114. Sensitive Periods for Cerebellar-Mediated Autistic-like Behaviors
  115. The mouse as a model for neuropsychiatric drug development
  116. The Way Forward for Mechanism-Based Therapeutics in Genetically Defined Neurodevelopmental Disorders
  117. A Unified Circuit for Social Behavior
  118. Abnormal mTOR Activation in Autism
  119. Author Correction: Neuronal activity regulates DROSHA via autophagy in spinal muscular atrophy
  120. Recurrence quantification analysis of resting state EEG signals in autism spectrum disorder – a systematic methodological exploration of technical and demographic confounders in the search for biomarkers
  121. Automated Detection of High Frequency Oscillations in Human Scalp Electroencephalogram
  122. Quantitative Apparent Diffusion Coefficient Mapping May Predict Seizure Onset in Children With Sturge-Weber Syndrome
  123. Visual and semi-automatic non-invasive detection of interictal fast ripples: A potential biomarker of epilepsy in children with tuberous sclerosis complex
  124. mTOR’ing across the Cortex by Chopping the Cilia
  125. Neuronal activity regulates DROSHA via autophagy in spinal muscular atrophy
  126. Vigabatrin for Epileptic Spasms and Tonic Seizures in Tuberous Sclerosis Complex
  127. Cerebellar volume as an imaging marker of development in infants with tuberous sclerosis complex
  128. A mouse model of DEPDC5 -related epilepsy: Neuronal loss of Depdc5 causes dysplastic and ectopic neurons, increased mTOR signaling, and seizure susceptibility
  129. Purkinje cells derived from TSC patients display hypoexcitability and synaptic deficits associated with reduced FMRP levels and reversed by rapamycin
  130. SPARK: A US Cohort of 50,000 Families to Accelerate Autism Research
  131. Placebo-controlled crossover assessment of mecasermin for the treatment of Rett syndrome
  132. mGluR5 Modulation of Behavioral and Epileptic Phenotypes in a Mouse Model of Tuberous Sclerosis Complex
  133. Clinical and genetic characterization of AP4B1 -associated SPG47
  134. Corpus Callosum White Matter Diffusivity Reflects Cumulative Neurological Comorbidity in Tuberous Sclerosis Complex
  135. Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders
  136. Presentation and Diagnosis of Tuberous Sclerosis Complex in Infants
  137. Utility of the Autism Observation Scale for Infants in Early Identification of Autism in Tuberous Sclerosis Complex
  138. Early autism symptoms in infants with tuberous sclerosis complex
  139. Aberrant Proteostasis of BMAL1 Underlies Circadian Abnormalities in a Paradigmatic mTOR-opathy
  140. Classification of respiratory disturbances in Rett Syndrome patients using Restricted Boltzmann Machine
  141. Autism spectrum disorder and epileptic encephalopathy: common causes, many questions
  142. Replicable in vivo physiological and behavioral phenotypes of the Shank3B null mutant mouse model of autism
  143. Defining Hand Stereotypies in Rett Syndrome: A Movement Disorders Perspective
  144. Increased Survival and Partly Preserved Cognition in a Patient With ACO2-Related Disease Secondary to a Novel Variant
  145. p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis
  146. Influence of seizures on early development in tuberous sclerosis complex
  147. Combination Clearance Therapy and Barbiturate Coma for Severe Carbamazepine Overdose
  148. Translational use of event-related potentials to assess circuit integrity in ASD
  149. Neuronal CTGF/CCN2 negatively regulates myelination in a mouse model of tuberous sclerosis complex
  150. Using tuberous sclerosis complex to understand the impact of MTORC1 signaling on mitochondrial dynamics and mitophagy in neurons
  151. Impaired Mitochondrial Dynamics And Mitophagy In Neuronal Models Of Tuberous Sclerosis Complex
  152. Somatic GNAQ mutation is enriched in brain endothelial cells in Sturge-Weber Syndrome
  153. Impaired Mitochondrial Dynamics and Mitophagy in Neuronal Models of Tuberous Sclerosis Complex
  154. The Pediatric Neurology Trainee Publication Award for 2015
  155. Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A
  156. Characterizing Multiscale Mechanical Properties of Brain Tissue Using Atomic Force Microscopy, Impact Indentation, and Rheometry
  157. Symptom profiles of autism spectrum disorder in tuberous sclerosis complex
  158. Effect of Angiofibromas on Quality of Life and Access to Care in Tuberous Sclerosis Patients and Their Caregivers
  159. Direct current stimulation induces mGluR5-dependent neocortical plasticity
  160. White and gray matter fiber pathways in autism spectrum disorder revealed by ex vivo diffusion MR tractography
  161. Leveraging a Sturge-Weber Gene Discovery: An Agenda for Future Research
  162. Sturge-Weber Syndrome: Brain Magnetic Resonance Imaging and Neuropathology Findings
  163. Editorial: Essential Pathways and Circuits of Autism Pathogenesis
  164. Advances and Future Directions for Tuberous Sclerosis Complex Research: Recommendations from the 2015 Strategic Planning Conference
  165. Cell-type-specific miR-431 dysregulation in a motor neuron model of spinal muscular atrophy
  166. Epileptogenesis in neurocutaneous disorders with focus in Sturge Weber syndrome
  167. Engineering microdeletions and microduplications by targeting segmental duplications with CRISPR
  168. Clinical Electroencephalographic Biomarker for Impending Epilepsy in Asymptomatic Tuberous Sclerosis Complex Infants
  169. Neurological Comorbidities in Autism Spectrum Disorder
  170. Essential Pathways and Circuits of Autism Pathogenesis
  171. Congenital disorders of autophagy: an emerging novel class of inborn errors of neuro-metabolism
  172. Disorders of Microtubule Function in Neurons: Imaging Correlates
  173. Super-resolution reconstruction in frequency, image, and wavelet domains to reduce through-plane partial voluming in MRI
  174. Mosaic and Intronic Mutations in TSC1/TSC2 Explain the Majority of TSC Patients with No Mutation Identified by Conventional Testing
  175. Adopting Rare Diseases
  176. Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders
  177. Tubers are neither static nor discrete
  178. Characterizing brain tissue by assessment of the distribution of anisotropic microstructural environments in diffusion-compartment imaging (DIAMOND)
  179. TSC2 controls neuronal development through FOXO1 and mitochondrial function in Autism Spectrum Disorders patient derived human neurons
  180. Cerebellar Development and Autism Spectrum Disorder in Tuberous Sclerosis Complex
  181. Pediatric Neurology 2014 Trainee Publication Award Winner: Dr. Mitchel T. Williams
  182. The Stress-Induced Atf3-Gelsolin Cascade Underlies Dendritic Spine Deficits in Neuronal Models of Tuberous Sclerosis Complex
  183. Developing therapies for spinal muscular atrophy
  184. Cerebellar associative sensory learning defects in five mouse autism models
  185. Therapeutic Advances in Autism and Other Neurodevelopmental Disorders
  186. Tuberous Sclerosis Complex
  187. Longitudinal Changes in Diffusion Properties in White Matter Pathways of Children With Tuberous Sclerosis Complex
  188. Visual Evoked Potentials as a Readout of Cortical Function in Infants With Tuberous Sclerosis Complex
  189. Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism
  190. The Circadian Protein BMAL1 Regulates Translation in Response to S6K1-Mediated Phosphorylation
  191. Autism and the synapse
  192. Vigabatrin can enhance electroretinographic responses in pigmented and albino rats
  193. Altered Structural Brain Networks in Tuberous Sclerosis Complex
  194. Tuberous Sclerosis Associated Neuropsychiatric Disorders (TAND) and the TAND Checklist
  195. Genetics of neurocutaneous disorders
  196. A Vascular Model of Tsc1 Deficiency Accelerates Renal Tumor Formation with Accompanying Hemangiosarcomas
  197. Gene Therapy for Childhood Neurological Disease
  198. The Neurology of mTOR
  199. Parkinson's disease: A disorder of axonal mitophagy?
  200. Somatic Mutations in Cerebral Cortical Malformations
  201. SMN regulates axonal local translation via miR-183/mTOR pathway
  202. Early developmental trajectories associated with ASD in infants with tuberous sclerosis complex
  203. Copy number variation plays an important role in clinical epilepsy
  204. RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity
  205. Mechanism-Based Treatment in Tuberous Sclerosis Complex
  206. Trust but Verify: The Introduction of Plagiarism Detection Software
  207. EphA7 signaling guides cortical dendritic development and spine maturation
  208. Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1
  209. A Mathematical Framework for the Registration and Analysis of Multi-Fascicle Models for Population Studies of the Brain Microstructure
  210. Autism Spectrum Disorders in Tuberous Sclerosis
  211. Divergent dysregulation of gene expression in murine models of fragile X syndrome and tuberous sclerosis
  212. Both Maternal and Pup Genotype Influence Ultrasonic Vocalizations and Early Developmental Milestones inTsc2+/−Mice
  213. Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
  214. Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
  215. Diffusion tensor imaging and related techniques in tuberous sclerosis complex: review and future directions
  216. A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS
  217. The Neuroprotective Drug Riluzole Acts via Small Conductance Ca2+-Activated K+ Channels to Ameliorate Defects in Spinal Muscular Atrophy Models
  218. SMA-MAP: A Plasma Protein Panel for Spinal Muscular Atrophy
  219. Pediatric Neurocritical Care: A Neurology Consultation Model and Implication for Education and Training
  220. Brain functional networks in syndromic and non-syndromic autism: a graph theoretical study of EEG connectivity
  221. A Magnetic Resonance Imaging Study of Cerebellar Volume in Tuberous Sclerosis Complex
  222. Fragile X Syndrome Therapeutics: Translation, Meet Translational Medicine
  223. Characterizing the DIstribution of Anisotropic MicrO-structural eNvironments with Diffusion-Weighted Imaging (DIAMOND)
  224. Prenatal Rapamycin Results in Early and Late Behavioral Abnormalities in Wildtype C57Bl/6 Mice
  225. Atypical Face Processing in Children With Tuberous Sclerosis Complex
  226. Targeted treatment trials for tuberous sclerosis and autism: no longer a dream
  227. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice
  228. Graded loss of tuberin in an allelic series of brain models of TSC correlates with survival, and biochemical, histological and behavioral features
  229. Homozygous PLCB1 deletion associated with malignant migrating partial seizures in infancy
  230. Impaired Language Pathways in Tuberous Sclerosis Complex Patients with Autism Spectrum Disorders
  231. Endothelial cell-fatty acid binding protein 4 promotes angiogenesis: role of stem cell factor/c-kit pathway
  232. Candidate Proteins, Metabolites and Transcripts in the Biomarkers for Spinal Muscular Atrophy (BforSMA) Clinical Study
  233. Evaluation of SMN Protein, Transcript, and Copy Number in the Biomarkers for Spinal Muscular Atrophy (BforSMA) Clinical Study
  234. Correction for Alexander et al., ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS
  235. Erratum: Gestational immune activation and Tsc2 haploinsufficiency cooperate to disrupt fetal survival and may perturb social behavior in adult mice
  236. Micro-duplications of 1q32.1 associated with neurodevelopmental delay
  237. Loss of White Matter Microstructural Integrity Is Associated with Adverse Neurological Outcome in Tuberous Sclerosis Complex
  238. Translational research
  239. Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex
  240. Febrile infection-related epilepsy syndrome (FIRES): Does duration of anesthesia affect outcome?
  241. A Genetic Model to Dissect the Role of Tsc-mTORC1 in Neuronal Cultures
  242. NMDA Mediated Contextual Conditioning Changes miRNA Expression
  243. Pediatric epileptology
  244. Febrile infection-related epilepsy syndrome (FIRES): Pathogenesis, treatment, and outcome
  245. Mechanisms of neurocognitive dysfunction and therapeutic considerations in tuberous sclerosis complex
  246. TSC1/TSC2 signaling in the CNS
  247. SMN Deficiency Reduces Cellular Ability to Form Stress Granules, Sensitizing Cells to Stress
  248. Neurocutaneous Syndromes
  249. MicroRNA Profiling Reveals Two Distinct p53-Related Human Pluripotent Stem Cell States
  250. Gestational immune activation and Tsc2 haploinsufficiency cooperate to disrupt fetal survival and may perturb social behavior in adult mice
  251. EphB-Mediated Degradation of the RhoA GEF Ephexin5 Relieves a Developmental Brake on Excitatory Synapse Formation
  252. The syndrome of perisylvian polymicrogyria with congenital arthrogryposis
  253. Eph receptor and mTOR pathway crosstalk: Implications for cancer
  254. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS
  255. Diffusion Features of White Matter in Tuberous Sclerosis With Tractography
  256. Tsc2-Rheb signaling regulates EphA-mediated axon guidance
  257. Maximum A Posteriori Estimation of Isotropic High-Resolution Volumetric MRI from Orthogonal Thick-Slice Scans
  258. Murine Glut-1 transporter haploinsufficiency: Postnatal deceleration of brain weight and reactive astrocytosis
  259. Tuberous Sclerosis Complex Activity Is Required to Control Neuronal Stress Responses in an mTOR-Dependent Manner
  260. Cardiac Rhabdomyomas in Tuberous Sclerosis Complex Show Apoptosis Regulation and mTOR Pathway Abnormalities
  261. Cardiac rhabdomyoma in tuberous sclerosis: Hyperactive Erk signaling
  262. Promoting Axon Regeneration in the Adult CNS by Modulation of the PTEN/mTOR Pathway
  263. Tuberous sclerosis complex proteins control axon formation
  264. Human CHN1 Mutations Hyperactivate  2-Chimaerin and Cause Duane's Retraction Syndrome
  265. Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function
  266. Loss of the Tuberous Sclerosis Complex Tumor Suppressors Triggers the Unfolded Protein Response to Regulate Insulin Signaling and Apoptosis
  267. Characterization of Autism in Young Children With Tuberous Sclerosis Complex
  268. Clinical Presentation and Diagnosis of Tuberous Sclerosis Complex in Infancy
  269. A Mouse Model of Tuberous Sclerosis: Neuronal Loss of Tsc1 Causes Dysplastic and Ectopic Neurons, Reduced Myelination, Seizure Activity, and Limited Survival
  270. Tuberous Sclerosis Complex and Epilepsy: Recent Developments and Future Challenges
  271. Neonatal Subependymal Giant Cell Astrocytoma: New Case and Review of Literature
  272. Cdk5 regulates EphA4-mediated dendritic spine retraction through an ephexin1-dependent mechanism
  273. S6K1 Regulates GSK3 under Conditions of mTOR-Dependent Feedback Inhibition of Akt
  274. Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities
  275. Deletion of chromosome 1p36 is associated with periventricular nodular heterotopia
  276. Regulation of EphA4 Kinase Activity Is Required for a Subset of Axon Guidance Decisions Suggesting a Key Role for Receptor Clustering in Eph Function
  277. Eph-Dependent Tyrosine Phosphorylation of Ephexin1 Modulates Growth Cone Collapse
  278. Vav Family GEFs Link Activated Ephs to Endocytosis and Axon Guidance
  279. Focal seizure and cerebral contrast retention after cardiac catheterization
  280. Prolonged treatment for acute symptomatic refractory status epilepticus
  281. Outcome of Severe Refractory Status Epilepticus in Children
  282. EphA Receptors Regulate Growth Cone Dynamics through the Novel Guanine Nucleotide Exchange Factor Ephexin
  283. Prolonged Treatment of Refractory Status Epilepticus in a Child
  284. Prolonged Treatment of Refractory Status Epilepticus in a Child
  285. Antiepileptic drug-induced visual hallucinations in a child
  286. Hydrocephalus associated with glycogen storage disease type II (pompe’s disease)
  287. Expression of PTPH1, a rat protein tyrosine phosphatase, is restricted to the derivatives of a specific diencephalic segment.
  288. Seven protein tyrosine phosphatases are differentially expressed in the developing rat brain
  289. Location of nicotinic and muscarinic cholinergic and μ-opiate receptors in rat cerebral neocortex: evidence from thalamic and cortical lesions
  290. Molecular identification of the lugaro cell in the cat cerebellar cortex